Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.

Biological psychiatry - 15 Oct 2012

Zhang Xiang Yang, Zhang Wu-Fang, Zhou Dong-Feng, Chen Da Chun, Xiu Mei Hong, Wu Hao-Ran, Haile Colin N, Kosten Therese A, Kosten Thomas R

Abstract excerpt

BACKGROUND: Tardive dyskinesia (TD) has no well-accepted treatments or known pathophysiology, but low brain-derived neurotrophic factor (BDNF) may play an important role in its pathophysiology. Ginkgo biloba (EGb-761) is a potent antioxidant that has neuroprotective effects mediated through enhancing BDNF levels. We hypothesized that treatment with EGb-761 would increase serum BDNF levels and reduce TD,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Brain-Derived Neurotrophic Factor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Methionine

Share to Movement Disorders

Share to Pharmacogenetics

Share to Plant Extracts

Share to Regression Analysis

Share to Valine

Source

Identifiers

PMID: 22695185
DOI: 10.1016/j.biopsych.2012.04.032

Genes

BDNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brain-derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba.PMID 22695185Read ↗

BDNF Val66Met polymorphism and antipsychotic-induced tardive dyskinesia occurrence and severity: a meta-analysis.Semantic proximity Read ↗

Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial.Semantic proximity Read ↗

No association between the brain-derived neurotrophic factor gene Val66Met polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia.Semantic proximity Read ↗

Genetic association of BDNF val66met and GSK-3beta-50T/C polymorphisms with tardive dyskinesia.Semantic proximity Read ↗

Effects of antipsychotics on the BDNF in schizophrenia.Semantic proximity Read ↗

Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Schizophrenia and Bipolar Disorder: A Systematic Review.Semantic proximity Read ↗

Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies.Semantic proximity Read ↗

BDNF Val66Met and clinical response to antipsychotic drugs: A systematic review and meta-analysis.Semantic proximity Read ↗

BDNF Val66Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizoaffective disorder patients: a meta-analysis.Semantic proximity Read ↗

Brain-derived neurotrophic factor and mental disorders.Semantic proximity Read ↗

Tardive Dyskinesia Development, Superoxide Dismutase Levels, and Relevant Genetic PolymorphismsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.